Jacobio Pharmaceuticals Group Co
Jacobio Pharmaceuticals Group Co., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug discovery and development. Founded in 2016, Jacobio has rapidly established itself in the oncology sector, focusing on the research and development of novel therapeutics that target cancer and other serious diseases. With a strong presence in major operational regions across Asia and beyond, Jacobio is renowned for its unique approach to drug design, particularly in the development of small molecule inhibitors. The company’s flagship products, including its promising pipeline of anti-cancer agents, highlight its commitment to addressing unmet medical needs. Recognised for its significant contributions to the biopharmaceutical industry, Jacobio Pharmaceuticals continues to enhance its market position through strategic partnerships and collaborations, aiming to deliver transformative therapies that improve patient outcomes globally.
DitchCarbon Score
How does Jacobio Pharmaceuticals Group Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jacobio Pharmaceuticals Group Co's score of 19 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Jacobio Pharmaceuticals Group Co's reported carbon emissions
In 2023, Jacobio Pharmaceuticals Group Co, headquartered in China (CN), reported total carbon emissions of approximately 2,705,100 kg CO2e. This figure includes 153,390 kg CO2e from Scope 1 emissions and 2,551,710 kg CO2e from Scope 2 emissions. In 2022, the company recorded total emissions of about 894,980 kg CO2e, with Scope 1 emissions at 148,170 kg CO2e and Scope 2 emissions at 2,406,860 kg CO2e. The 2021 emissions data showed a total of approximately 2,490,220 kg CO2e, comprising 58,370 kg CO2e from Scope 1 and 2,431,850 kg CO2e from Scope 2. Despite these figures, Jacobio Pharmaceuticals has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of climate pledges or commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 58,370 | 000,000 | 000,000 |
| Scope 2 | 2,431,850 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jacobio Pharmaceuticals Group Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
